GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Merck & Co Inc (NYSE:MRK) » Definitions » Cyclically Adjusted PB Ratio

Merck (MRK) Cyclically Adjusted PB Ratio : 7.77 (As of Apr. 27, 2024)


View and export this data going back to 1949. Start your Free Trial

What is Merck Cyclically Adjusted PB Ratio?

As of today (2024-04-27), Merck's current share price is $131.20. Merck's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $16.88. Merck's Cyclically Adjusted PB Ratio for today is 7.77.

The historical rank and industry rank for Merck's Cyclically Adjusted PB Ratio or its related term are showing as below:

MRK' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 3.04   Med: 4.12   Max: 7.82
Current: 7.74

During the past years, Merck's highest Cyclically Adjusted PB Ratio was 7.82. The lowest was 3.04. And the median was 4.12.

MRK's Cyclically Adjusted PB Ratio is ranked worse than
91.34% of 647 companies
in the Drug Manufacturers industry
Industry Median: 1.75 vs MRK: 7.74

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Merck's adjusted book value per share data for the three months ended in Dec. 2023 was $14.845. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $16.88 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Merck Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Merck's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Merck Cyclically Adjusted PB Ratio Chart

Merck Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.14 4.83 4.67 6.57 6.46

Merck Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.23 6.75 6.01 6.46 -

Competitive Comparison of Merck's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - General subindustry, Merck's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Merck's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Merck's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Merck's Cyclically Adjusted PB Ratio falls into.



Merck Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Merck's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=131.20/16.88
=7.77

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Merck's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Merck's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=14.845/129.4194*129.4194
=14.845

Current CPI (Dec. 2023) = 129.4194.

Merck Quarterly Data

Book Value per Share CPI Adj_Book
201403 17.059 99.695 22.145
201406 16.677 100.560 21.463
201409 15.808 100.428 20.371
201412 17.140 99.070 22.391
201503 16.888 99.621 21.939
201506 16.448 100.684 21.142
201509 16.268 100.392 20.972
201512 16.064 99.792 20.833
201603 15.817 100.470 20.374
201606 15.677 101.688 19.952
201609 15.840 101.861 20.125
201612 14.584 101.863 18.529
201703 14.537 102.862 18.290
201706 14.471 103.349 18.121
201709 14.029 104.136 17.435
201712 12.733 104.011 15.843
201803 12.504 105.290 15.370
201806 12.183 106.317 14.830
201809 12.194 106.507 14.817
201812 10.299 105.998 12.575
201903 10.661 107.251 12.865
201906 10.766 108.070 12.893
201909 10.521 108.329 12.569
201912 10.204 108.420 12.180
202003 10.382 108.902 12.338
202006 10.929 108.767 13.004
202009 11.537 109.815 13.597
202012 10.006 109.897 11.784
202103 10.645 111.754 12.328
202106 13.145 114.631 14.841
202109 14.174 115.734 15.850
202112 15.107 117.630 16.621
202203 16.170 121.301 17.252
202206 17.070 125.017 17.671
202209 17.549 125.227 18.137
202212 18.122 125.222 18.729
202303 18.457 127.348 18.757
202306 15.237 128.729 15.319
202309 16.269 129.860 16.214
202312 14.845 129.419 14.845

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Merck  (NYSE:MRK) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Merck Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Merck's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Merck (MRK) Business Description

Address
126 East Lincoln Avenue, Rahway, NJ, USA, 07065
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
Executives
Johannes Jacobus Oosthuizen officer: SVP, U.S. Market 2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Richard R. Deluca officer: EVP&Pres, Merck Animal Heallth 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Steven Mizell officer: EVP,Human Resources 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Joseph Romanelli officer: President, Human Health Int?l 126 EAST LINCOLN AVENUE, RAHWAY NJ 07065
Rita A Karachun officer: Sr. VP Fince-Global Controller 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Jennifer Zachary officer: EVP, General Counsel 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
David Michael Williams officer: EVP,Chief Info&Digital Officer MERCK & CO., INC., 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Robert M Davis officer: Evp, Global Svcs & CFO 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Sanat Chattopadhyay officer: Exe V-P & Pres. MMD 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Kenneth C Frazier officer: Chairman, President & CEO 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Chirfi Guindo officer: Chief Marketing Officer C/O BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142
Baker Douglas M Jr director 370 WBASHA ST NORTH, ST PAUL MN 55102
Arpa Garay officer: SVP Human Health Global Mktg. 2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Caroline Litchfield officer: EVP & CFO 2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Julie L. Gerberding officer: EVP Strat Comm, GI Pub Policy 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033

Merck (MRK) Headlines

From GuruFocus

Merck & Co Inc Annual Shareholders Meeting Transcript

By GuruFocus Research 01-23-2024

Q1 2023 Merck & Co Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q3 2022 Merck & Co Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Merck & Co Inc at Citi BioPharma Conference Transcript

By GuruFocus Research 01-23-2024

Merck & Co Inc at UBS BioPharma Conference Transcript

By GuruFocus Research 01-23-2024

Merck & Co Inc Annual Shareholders Meeting Transcript

By GuruFocus Research 01-23-2024

Q2 2023 Merck & Co Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024